Somatic mosaicism for a lethal TRPV4 mutation results in non-lethal metatropic dysplasia

Michael M Weinstein1, Taekyu Kang2, Ralph S Lachman3

  • 1Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles.

Insights

Somatic mosaicism for TRPV4 mutations can cause metatropic dysplasia with milder symptoms. High-throughput sequencing improves detection of these TRPV4 genetic variants.

Area of Science:

  • Genetics
  • Molecular Biology
  • Skeletal Dysplasias

Background:

  • Dominant mutations in TRPV4 (Transient Receptor Potential Cation Channel Subfamily V Member 4) are linked to musculoskeletal disorders, including peripheral neuropathies and skeletal dysplasias.
  • Phenotypes range from brachyolmia to lethal metatropic dysplasia.

Observation:

  • A case presented with metatropic dysplasia features but lacked detectable TRPV4 mutations via Sanger sequencing.
  • Exome sequencing revealed a known lethal metatropic dysplasia TRPV4 mutation (TRPV4L618P) at a lower than expected frequency.

Findings:

  • The individual was diagnosed with somatic mosaicism for the TRPV4L618P mutation.
  • This mosaic state explains the milder-than-expected clinical presentation.

Implications:

  • High-throughput sequencing offers higher sensitivity for detecting mosaicism compared to Sanger sequencing.
  • Somatic mosaicism represents a novel genetic mechanism contributing to metatropic dysplasia.
  • This finding expands the understanding of TRPV4-related skeletal disorders.